Cooley advised the underwriters on Catabasis Pharmaceuticals' $69 million initial public offering. Catabasis is a Massachusetts-based clinical-stage biopharmaceutical company focused on the discovery and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker technology platform. The SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The company's common stock trades on the Nasdaq Global Market under the symbol "CATB."
Citigroup Capital Markets and Cowen and Co. acted as joint book-running managers for the offering. Oppenheimer & Co. and Wedbush PacGrow acted as co-managers.